Mallinckrodt completes rolling submission of new drug application to the fda for terlipressin

Mallinckrodt completes rolling submission of new drug application to the u.s. food and drug administration (fda) for terlipressin for the treatment of patients with hepatorenal syndrome type 1 (hrs-1).
MNK Ratings Summary
MNK Quant Ranking